Comparing efficacy of antiviral prophylaxis to vaccination in prevention of varicella zoster in patients post-hematopoietic stem cell transplant
Abstract
Varicella Zoster Virus (VZV) is a source of morbidity and mortality in patients post hematopoietic stem cell transplant. Both antiviral prophylaxis and vaccination are current measures to prevent infection or reactivation with the virus, but guidelines differ widely on recommendations, and some recommend against vaccination altogether. This review compares vaccination in the prevention of herpes zoster infections in patients who have undergone a hematopoietic stem cell transplant compared with antiviral prophylaxis.
Comparing efficacy of antiviral prophylaxis to vaccination in prevention of varicella zoster in patients post-hematopoietic stem cell transplant
Varicella Zoster Virus (VZV) is a source of morbidity and mortality in patients post hematopoietic stem cell transplant. Both antiviral prophylaxis and vaccination are current measures to prevent infection or reactivation with the virus, but guidelines differ widely on recommendations, and some recommend against vaccination altogether. This review compares vaccination in the prevention of herpes zoster infections in patients who have undergone a hematopoietic stem cell transplant compared with antiviral prophylaxis.
